{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:05:51Z","timestamp":1785913551924,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016273","name":"Menarini Silicon Biosystems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.esmoop.2025.105302","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:51:50Z","timestamp":1750171910000},"page":"105302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Blood tumor load: combining biomarkers to increase the proportion of informative patients"],"prefix":"10.1016","volume":"10","author":[{"given":"E.","family":"Dathathri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.W.","family":"Coumans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105302_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105302_bib2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/cancers15051579","article-title":"Liquid biopsies, novel approaches and future directions","volume":"15","author":"Armakolas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105302_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.863472","article-title":"Liquid biopsy based circulating biomarkers in metastatic prostate cancer","volume":"12","author":"Dathathri","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105302_bib4","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.3390\/cancers13225723","article-title":"Biomarkers for treatment response in advanced prostate cancer","volume":"13","author":"Asif","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105302_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13323","article-title":"Biomarkers: promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases","volume":"9","author":"Bodaghi","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105302_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdr263","article-title":"High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients","volume":"23","author":"Pierga","year":"2012","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105302_bib7","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105302_bib8","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105302_bib9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mds625","article-title":"Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer","volume":"24","author":"Ligthart","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105302_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-020-01323-5","article-title":"HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer","volume":"22","author":"Nanou","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105302_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdq030","article-title":"All circulating EpCAM+CK+CD45\u2212 objects predict overall survival in castration-resistant prostate cancer","volume":"21","author":"Coumans","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105302_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41416-019-0726-9","article-title":"Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival","volume":"122","author":"Nanou","year":"2020","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105302_bib13","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-12-1585","article-title":"Challenges in the enumeration and phenotyping of CTC","volume":"18","author":"Coumans","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"40","key":"10.1016\/j.esmoop.2025.105302_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105302_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cells13040337","article-title":"Extracellular vesicles, circulating tumor cells, and immune checkpoint inhibitors: hints and promises","volume":"13","author":"Bandini","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105302_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in cancer: cell-to-cell mediators of metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105302_bib17","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105302_bib18","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.3390\/cancers14184404","article-title":"Characterizing circulating tumor cells and tumor-derived extracellular vesicles in metastatic castration-naive and castration-resistant prostate cancer patients","volume":"14","author":"Isebia","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105302_bib19","doi-asserted-by":"crossref","first-page":"19283","DOI":"10.18632\/oncotarget.25019","article-title":"Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients","volume":"9","author":"Nanou","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2025.105302_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102064","article-title":"Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors","volume":"88","author":"Dieci","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105302_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105302_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105302_bib23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105302_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105302_bib25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105302_bib26","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105302_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105302_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105302_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cyto.a.20369","article-title":"Statistical considerations for enumeration of circulating tumor cells","volume":"71A","author":"Tibbe","year":"2007","journal-title":"Cytometry A"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105302_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186562","article-title":"Quantifying HER-2 expression on circulating tumor cells by ACCEPT","volume":"12","author":"Zeune","year":"2017","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105302_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105302_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euf.2016.09.005","article-title":"Interrogating metastatic prostate cancer treatment switch decisions: a multi-institutional survey","volume":"4","author":"Lorente","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105302_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1593\/tlo.12247","article-title":"Interpretation of changes in circulating tumor cell counts","volume":"5","author":"Coumans","year":"2012","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105302_bib34","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/annonc\/mdy172","article-title":"Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts","volume":"29","author":"Lorente","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105302_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1756287213513488","article-title":"The Prostate Health Index: a new test for the detection of prostate cancer","volume":"6","author":"Loeb","year":"2014","journal-title":"Ther Adv Urol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105302_bib36","first-page":"3","article-title":"Finding the wolf in sheep's clothing: the 4Kscore is a novel blood test that can accurately identify the risk of aggressive prostate cancer","volume":"17","author":"Punnen","year":"2015","journal-title":"Rev Urol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105302_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.06.002","article-title":"Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: a prospective, multicenter study","volume":"40","author":"Klein","year":"2022","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105302_bib38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105302_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105302_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2009.07.047","article-title":"Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort","volume":"56","author":"Vickers","year":"2009","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105302_bib41","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.3390\/cancers14122916","article-title":"StarDist image segmentation improves circulating tumor cell detection","volume":"14","author":"Stevens","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105302_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s42256-020-0153-x","article-title":"Deep learning of circulating tumour cells","volume":"2","author":"Zeune","year":"2020","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.esmoop.2025.105302_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/pnasnexus\/pgae048","article-title":"Training an automated circulating tumor cell classifier when the true classification is uncertain","volume":"3","author":"Nanou","year":"2024","journal-title":"PNAS Nexus"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105302_bib44","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","article-title":"Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer","volume":"22","author":"Janni","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105302_bib45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3892\/ijo.2015.2824","article-title":"Importance of circulating tumor cells in newly diagnosed colorectal cancer","volume":"46","author":"van Dalum","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.esmoop.2025.105302_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-4939-2990-0_18","article-title":"Terstappen LWMM Detection and characterization of circulating tumor cells by the CellSearch approach","volume":"1347","author":"Coumans","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105302_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-023-01880-1","article-title":"Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis","volume":"22","author":"Stoecklein","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2025.105302_bib48","article-title":"The prognostic value of plasma cell-free DNA concentration in the prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:00:08Z","timestamp":1755496808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2059702925011718"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105302","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood tumor load: combining biomarkers to increase the proportion of informative patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105302"}}